Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 5
Submit an article Journal homepage
2,658
Views
77
CrossRef citations to date
0
Altmetric
Original Research

TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade

V. Cervera-CarrasconTILT Biotherapeutics Ltd, Helsinki, Uusima, Finland;Department of Oncology, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Uusima, FinlandORCID Iconhttp://orcid.org/0000-0001-6684-3666
ORCID Icon,
M. SiuralaTILT Biotherapeutics Ltd, Helsinki, Uusima, Finland;Department of Oncology, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Uusima, Finland
,
J. M. SantosTILT Biotherapeutics Ltd, Helsinki, Uusima, Finland;Department of Oncology, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Uusima, Finland
,
R. HavunenTILT Biotherapeutics Ltd, Helsinki, Uusima, Finland;Department of Oncology, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Uusima, Finland
,
S. TähtinenDepartment of Oncology, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Uusima, Finland
,
P. KarellInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Uusima, FinlandORCID Iconhttp://orcid.org/0000-0001-5312-243X
ORCID Icon,
S. SorsaTILT Biotherapeutics Ltd, Helsinki, Uusima, Finland;Department of Oncology, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Uusima, Finland
,
A. KanervaDepartment of Oncology, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Uusima, Finland;Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Uusima, Finland
&
A. HemminkiTILT Biotherapeutics Ltd, Helsinki, Uusima, Finland;Department of Oncology, Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Uusima, Finland;Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Uusima, FinlandCorrespondence[email protected]
 show all
Article: e1412902 | Received 04 Oct 2017, Accepted 20 Nov 2017, Published online: 09 Apr 2018

Citations (77)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (9)

Tatiana V. Kudling, James H.A. Clubb, Santeri Pakola, Dafne C.A. Quixabeira, Iris A.K. Lähdeniemi, Camilla Heiniö, Victor Arias, Riikka Havunen, Victor Cervera-Carrascon, Joao M. Santos, Eva Sutinen, Jari Räsänen, Kristian Borenius, Mikko I. Mäyränpää, Eero Aaltonen, Suvi Sorsa, Otto Hemminki, Anna Kanerva, Emmy W. Verschuren, Ilkka Ilonen & Akseli Hemminki. (2023) Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer. OncoImmunology 12:1.
Read now
Dafne C. A. Quixabeira, Victor Cervera-Carrascon, Joao M. Santos, James H.A. Clubb, Tatiana V. Kudling, Saru Basnet, Camilla Heiniö, Susanna Grönberg-Vähä-Koskela, Marjukka Anttila, Riikka Havunen, Anna Kanerva & Akseli Hemminki. (2022) Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1. OncoImmunology 11:1.
Read now
Shao-Chia Lu & Michael A Barry. (2022) Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses. Expert Opinion on Biological Therapy 22:11, pages 1359-1378.
Read now
Matthew Chiu, Edward John Lloyd Armstrong, Vicki Jennings, Shane Foo, Eva Crespo-Rodriguez, Galabina Bozhanova, Emmanuel Christian Patin, Martin McLaughlin, David Mansfield, Gabriella Baker, Lorna Grove, Malin Pedersen, Joan Kyula, Victoria Roulstone, Anna Wilkins, Fiona McDonald, Kevin Harrington & Alan Melcher. (2020) Combination therapy with oncolytic viruses and immune checkpoint inhibitors. Expert Opinion on Biological Therapy 20:6, pages 635-652.
Read now
Victor Cervera-Carrascon, Dafne C.A. Quixabeira, Joao Manuel Santos, Riikka Havunen, Sadia Zafar, Otto Hemminki, Camilla Heiniö, Eleonora Munaro, Mikko Siurala, Suvi Sorsa, Tuomas Mirtti, Petrus Järvinen, Markus Mildh, Harry Nisen, Antti Rannikko, Marjukka Anttila, Anna Kanerva & Akseli Hemminki. (2020) Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. OncoImmunology 9:1.
Read now
Victor Cervera-Carrascon, Riikka Havunen & Akseli Hemminki. (2019) Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.. Expert Opinion on Biological Therapy 19:5, pages 443-455.
Read now
Lukasz Kuryk, Anne-Sophie W. Møller & Magnus Jaderberg. (2019) Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. OncoImmunology 8:2.
Read now
Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean-Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology 7:12.
Read now
Sadia Zafar, Suvi Sorsa, Mikko Siurala, Otto Hemminki, Riikka Havunen, Victor Cervera-Carrascon, João Manuel Santos, Hongjie Wang, Andre Lieber, Tanja De Gruijl, Anna Kanerva & Akseli Hemminki. (2018) CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. OncoImmunology 7:10.
Read now

Articles from other publishers (68)

Priya Hays. 2024. Viral Replication Cycle [Working Title]. Viral Replication Cycle [Working Title].
Jia Yi, Peizhe Lin, Qingbo Li, Ao Zhang & Xianbin Kong. (2023) A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon. Molecular Therapy - Oncolytics 30, pages 254-274.
Crossref
Peter Kok-Ting Wan, Ricardo A Fernandes & Leonard W Seymour. (2023) Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?. Journal for ImmunoTherapy of Cancer 11:8, pages e006518.
Crossref
Minji Choi, Jisoo Shin, Chae-Eun Lee, Joo-Yoon Chung, Minji Kim, Xiuwen Yan, Wen-Hao Yang & Jong-Ho Cha. (2023) Immunogenic cell death in cancer immunotherapy. BMB Reports 56:5, pages 275-286.
Crossref
Aleksander Gryciuk, Marta Rogalska, Joanna Baran, Lukasz Kuryk & Monika Staniszewska. (2023) Oncolytic Adenoviruses Armed with Co-Stimulatory Molecules for Cancer Treatment. Cancers 15:7, pages 1947.
Crossref
James H. A. Clubb, Tatiana V. Kudling, Mykhailo Girych, Lyna Haybout, Santeri Pakola, Firas Hamdan, Víctor Cervera-Carrascon, Annabrita Hemmes, Susanna Grönberg-Vähä-Koskela, João Manuel Santos, Dafne C. A. Quixabeira, Saru Basnet, Camilla Heiniö, Victor Arias, Elise Jirovec, Shreyas Kaptan, Riikka Havunen, Suvi Sorsa, Abdullah Erikat, Joel Schwartz, Marjukka Anttila, Katri Aro, Tapani Viitala, Ilpo Vattulainen, Vincenzo Cerullo, Anna Kanerva & Akseli Hemminki. (2023) Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting. Frontiers in Immunology 14.
Crossref
Hui Dong, Mengli Li, Chen Yang, Wei Wei, Xianglei He, Gang Cheng & Shibing Wang. (2023) Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. Cancer Cell International 23:1.
Crossref
Ioana Rada Popa Ilie & Carmen Emanuela Georgescu. (2023) Immunotherapy in Gastroenteropancreatic Neuroendocrine Neoplasia. Neuroendocrinology 113:2, pages 262-278.
Crossref
Mariam Oladejo, Wyatt Paulishak & Laurence Wood. (2023) Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Seminars in Cancer Biology 88, pages 81-95.
Crossref
Hai Zou, Xiao‐Zhou Mou & Biao Zhu. (2022) Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic. Global Challenges 7:1.
Crossref
Maya A. Dymova, Anna S. Kichkailo, Elena V. Kuligina & Vladimir A. Richter. (2022) Aptamers Enhance Oncolytic Viruses’ Antitumor Efficacy. Pharmaceutics 15:1, pages 151.
Crossref
Hong-My Nguyen, Praveen K. Bommareddy, Ann W. Silk & Dipongkor Saha. (2022) Optimal timing of PD-1 blockade in combination with oncolytic virus therapy. Seminars in Cancer Biology 86, pages 971-980.
Crossref
Ee Wern Tan, Noraini Abd-Aziz, Chit Laa Poh & Kuan Onn Tan. (2022) Engineered Oncolytic Adenoviruses: An Emerging Approach for Cancer Therapy. Pathogens 11:10, pages 1146.
Crossref
Karina Spunde, Ksenija Korotkaja & Anna Zajakina. (2022) Recombinant Viral Vectors for Therapeutic Programming of Tumour Microenvironment: Advantages and Limitations. Biomedicines 10:9, pages 2142.
Crossref
Chae-Ok Yun, JinWoo Hong & A-Rum Yoon. (2022) Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. Frontiers in Immunology 13.
Crossref
S. Feola, S. Russo, E. Ylösmäki & V. Cerullo. (2022) Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. Pharmacology & Therapeutics 236, pages 108103.
Crossref
Sintayehu Tsegaye Tseha. (2022) Role of Adenoviruses in Cancer Therapy. Frontiers in Oncology 12.
Crossref
Ramazan Rezaei, Hadi Esmaeili Gouvarchin Ghaleh, Mahdieh Farzanehpour, Ruhollah Dorostkar, Reza Ranjbar, Masoumeh Bolandian, Majid Mirzaei Nodooshan & Akbar Ghorbani Alvanegh. (2021) Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy. Cancer Gene Therapy 29:6, pages 647-660.
Crossref
Maria Vitale, Filippo Scialò, Margherita Passariello, Eleonora Leggiero, Anna D’Agostino, Lorella Tripodi, Laura Gentile, Andrea Bianco, Giuseppe Castaldo, Vincenzo Cerullo, Claudia De Lorenzo & Lucio Pastore. (2022) Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model. Frontiers in Oncology 12.
Crossref
James H. A. Clubb, Tatiana V. Kudling, Camilla Heiniö, Saru Basnet, Santeri Pakola, Víctor Cervera Carrascón, João Manuel Santos, Dafne C. A. Quixabeira, Riikka Havunen, Suvi Sorsa, Vincent Zheng, Tuula Salo, Leif Bäck, Katri Aro, Sanni Tulokas, Venla Loimu & Akseli Hemminki. (2022) Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer. Frontiers in Immunology 13.
Crossref
Jessica Wenthe, Sedigheh Naseri, Ann-Charlotte Hellström, Rafael Moreno, Gustav Ullenhag, Ramon Alemany, Tanja Lövgren, Emma Eriksson & Angelica Loskog. (2022) Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition. Molecular Therapy - Oncolytics 24, pages 429-442.
Crossref
Lydia G. White, Hannah E. Goy, Alinor J. Rose & Alexander D. McLellan. (2022) Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours. Cancers 14:4, pages 978.
Crossref
Christine E. Boone, Lu Wang, Aayushma Gautam, Isabel G. Newton & Nicole F. Steinmetz. (2021) Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. WIREs Nanomedicine and Nanobiotechnology 14:1.
Crossref
Hai-Jun Hu, Xiu Liang, Hai-Lang Li, Huai-Yuan Wang, Jin-Fa Gu, Lan-Ying Sun, Jing Xiao, Jin-Qing Hu, Ai-Min Ni & Xin-Yuan Liu. (2021) Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model. Cancer Immunology, Immunotherapy 70:12, pages 3541-3555.
Crossref
Anqi Lin, Hongman Zhang, Hui Meng, Ze Deng, Tianqi Gu, Peng Luo & Jian Zhang. (2021) TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Frontiers in Immunology 12.
Crossref
Drew Ashton Boagni, Divya Ravirala & Shaun Xiaoliu Zhang. (2021) Current strategies in engaging oncolytic viruses with antitumor immunity. Molecular Therapy - Oncolytics 22, pages 98-113.
Crossref
Jianhan Huang, Meijun Zheng, Zongliang Zhang, Xin Tang, Yaxing Chen, Aijun Peng, Xingchen Peng, Aiping Tong & Liangxue Zhou. (2021) Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunology, Immunotherapy 70:9, pages 2453-2465.
Crossref
Victor Cervera-Carrascon, Dafne C. A. Quixabeira, Joao M. Santos, Riikka Havunen, Ioanna Milenova, Jan Verhoeff, Camilla Heiniö, Sadia Zafar, Juan J. Garcia-Vallejo, Victor W. van Beusechem, Tanja D. de Gruijl, Aino Kalervo, Suvi Sorsa, Anna Kanerva & Akseli Hemminki. (2021) Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1. Frontiers in Immunology 12.
Crossref
Yaqi Zhao, Zheming Liu, Lan Li, Jie Wu, Huibo Zhang, Haohan Zhang, Tianyu Lei & Bin Xu. (2021) Oncolytic Adenovirus: Prospects for Cancer Immunotherapy. Frontiers in Microbiology 12.
Crossref
Chen Yang, Nanni Hua, Shufang Xie, Yi Wu, Lifeng Zhu, Shibing Wang & Xiangmin Tong. (2021) Oncolytic viruses as a promising therapeutic strategy for hematological malignancies. Biomedicine & Pharmacotherapy 139, pages 111573.
Crossref
Martí Farrera-Sal, Laura Moya-Borrego, Miriam Bazan-Peregrino & Ramon Alemany. (2021) Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus. Clinical Cancer Research 27:11, pages 2979-2988.
Crossref
Hui-Kung Ting, Chin-Li Chen, En Meng, Juin-Hong Cherng, Shu-Jen Chang, Chien-Chang Kao, Ming-Hsin Yang, Fang-Shiuan Leung & Sheng-Tang Wu. (2021) Inflammatory Regulation by TNF-α-Activated Adipose-Derived Stem Cells in the Human Bladder Cancer Microenvironment. International Journal of Molecular Sciences 22:8, pages 3987.
Crossref
Estela Núñez-Manchón, Martí Farrera-Sal, Marc Otero-Mateo, Giancarlo Castellano, Rafael Moreno, David Medel, Ramon Alemany, Eneko Villanueva & Cristina Fillat. (2021) Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenoviruses. NAR Cancer 3:2.
Crossref
Lorella Tripodi, Maria Vitale, Vincenzo Cerullo & Lucio Pastore. (2021) Oncolytic Adenoviruses for Cancer Therapy. International Journal of Molecular Sciences 22:5, pages 2517.
Crossref
Ioanna Milenova, Marta Lopez Gonzalez, Dafne C.A. Quixabeira, Joao Manuel SantosVictor Cervera-Carrascon, Wenliang Dong, Akseli HemminkiVictor W. van Beusechem, Rieneke van de Ven & Tanja D. de Gruijl. (2021) Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma. Human Gene Therapy 32:3-4, pages 178-191.
Crossref
Riikka Havunen, Riikka Kalliokoski, Mikko Siurala, Suvi Sorsa, João M. Santos, Victor Cervera-Carrascon, Marjukka Anttila & Akseli Hemminki. (2021) Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1. Cells 10:2, pages 246.
Crossref
Gan-Qing Xia, Tian-Run Lei, Teng-Bo Yu & Pang-Hu Zhou. (2021) Nanocarrier-based activation of necroptotic cell death potentiates cancer immunotherapy. Nanoscale 13:2, pages 1220-1230.
Crossref
Otto Hemminki, João Manuel dos Santos & Akseli Hemminki. (2020) Oncolytic viruses for cancer immunotherapy. Journal of Hematology & Oncology 13:1.
Crossref
Jonathan G. Pol, Samuel T. Workenhe, Prathyusha Konda, Shashi Gujar & Guido Kroemer. (2020) Cytokines in oncolytic virotherapy. Cytokine & Growth Factor Reviews 56, pages 4-27.
Crossref
Lisa A. Santry, Jacob P. van Vloten, Jason P. Knapp, Kathy Matuszewska, Thomas M. McAusland, Jessica A. Minott, Robert C. Mould, Ashley A. Stegelmeier, Pierre P. Major, Sarah K. Wootton, James J. Petrik & Byram W. Bridle. (2020) Tumour vasculature: Friend or foe of oncolytic viruses?. Cytokine & Growth Factor Reviews 56, pages 69-82.
Crossref
Taylor R. Jamieson, Joanna Poutou & Carolina S. Ilkow. (2020) Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment. Cytokine & Growth Factor Reviews 56, pages 102-114.
Crossref
Tabitha G. Cunliffe, Emily A. Bates & Alan L. Parker. (2020) Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies. Cancers 12:11, pages 3327.
Crossref
Lukasz Kuryk, Laura Bertinato, Monika Staniszewska, Katarzyna Pancer, Magdalena Wieczorek, Stefano Salmaso, Paolo Caliceti & Mariangela Garofalo. (2020) From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. Cancers 12:10, pages 3057.
Crossref
Chang-Myung Oh, Hong Jae Chon & Chan Kim. (2020) Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors. International Journal of Molecular Sciences 21:20, pages 7743.
Crossref
Erkko Ylösmäki & Vincenzo Cerullo. (2020) Design and application of oncolytic viruses for cancer immunotherapy. Current Opinion in Biotechnology 65, pages 25-36.
Crossref
María Alejandra Gleisner, Cristián Pereda, Andrés Tittarelli, Mariela Navarrete, Camila Fuentes, Ignacio Ávalos, Fabian Tempio, Juan Pablo Araya, María Inés Becker, Fermín Eduardo González, Mercedes Natalia López & Flavio Salazar-Onfray. (2020) A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth. Journal for ImmunoTherapy of Cancer 8:2, pages e000999.
Crossref
Victor Cervera-Carrascon, Dafne C.A. Quixabeira, Riikka Havunen, Joao M. Santos, Emma Kutvonen, James H.A. Clubb, Mikko Siurala, Camilla Heiniö, Sadia Zafar, Teija Koivula, Dave Lumen, Marjo Vaha, Arturo Garcia-Horsman, Anu J. Airaksinen, Suvi Sorsa, Marjukka Anttila, Veijo Hukkanen, Anna Kanerva & Akseli Hemminki. (2020) Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. Molecular Therapy - Oncolytics 17, pages 47-60.
Crossref
Mizuho Sato-Dahlman, Christopher J. LaRocca, Chikako Yanagiba & Masato Yamamoto. (2020) Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination. Cancers 12:5, pages 1295.
Crossref
Christianne Groeneveldt, Thorbald van Hall, Sjoerd H. van der Burg, Peter ten Dijke & Nadine van Montfoort. (2020) Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses. Trends in Immunology 41:5, pages 406-420.
Crossref
Tao Shi, Xueru Song, Yue Wang, Fangcen Liu & Jia Wei. (2020) Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. Frontiers in Immunology 11.
Crossref
Martí Farrera-Sal, Cristina Fillat & Ramon Alemany. (2020) Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses. Cancers 12:4, pages 1034.
Crossref
Sara Saab, Hussein Zalzale, Zahraa Rahal, Yara Khalifeh, Ansam Sinjab & Humam Kadara. (2020) Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Frontiers in Immunology 11.
Crossref
Zijun Zhao, Xiaoyun Xiao, Phei Er Saw, Wei Wu, Hongyan Huang, Jiewen Chen & Yan Nie. (2019) Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Science China Life Sciences 63:2, pages 180-205.
Crossref
Won Jin Ho, Mark Yarchoan, Soren Charmsaz, Rebecca M. Munday, Ludmila Danilova, Marcelo B. Sztein, Elana J. Fertig & Elizabeth M. Jaffee. (2020) Multipanel mass cytometry reveals anti–PD-1 therapy–mediated B and T cell compartment remodeling in tumor-draining lymph nodes. JCI Insight 5:2.
Crossref
João Manuel Santos, Camilla Heiniö, Victor Cervera-Carrascon, Dafne C A Quixabeira, Mikko Siurala, Riikka Havunen, Ralf Butzow, Sadia Zafar, Tanja de Gruijl, Heini Lassus, Anna Kanerva & Akseli Hemminki. (2020) Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity. Journal for ImmunoTherapy of Cancer 8:1, pages e000188.
Crossref
João Manuel Santos, Riikka Havunen & Akseli Hemminki. 2020. Tumor Immunology and Immunotherapy – Integrated Methods Part A. Tumor Immunology and Immunotherapy – Integrated Methods Part A 205 230 .
Amanda Rosewell Shaw & Masataka Suzuki. (2019) Immunology of Adenoviral Vectors in Cancer Therapy. Molecular Therapy - Methods & Clinical Development 15, pages 418-429.
Crossref
Luke Russell, Kah Whye Peng, Stephen J. Russell & Rosa Maria Diaz. (2019) Oncolytic Viruses: Priming Time for Cancer Immunotherapy. BioDrugs 33:5, pages 485-501.
Crossref
Lukasz Kuryk, Anne‐Sophie W. Møller & Magnus Jaderberg. (2019) Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma. Journal of Medical Virology 91:9, pages 1702-1706.
Crossref
Anne Montfort, Céline Colacios, Thierry Levade, Nathalie Andrieu-Abadie, Nicolas Meyer & Bruno Ségui. (2019) The TNF Paradox in Cancer Progression and Immunotherapy. Frontiers in Immunology 10.
Crossref
Stefanie Maurer, Helmut Salih, Irina Smirnow, Ulrich Lauer & Susanne Berchtold. (2019) Suicide gene‑armed measles vaccine virus for the treatment of AML. International Journal of Oncology.
Crossref
Venkatesh Sivanandam, Christopher J. LaRocca, Nanhai G. Chen, Yuman Fong & Susanne G. Warner. (2019) Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds. Molecular Therapy - Oncolytics 13, pages 93-106.
Crossref
Chune Yu, Xiaowei Liu, Jiqiao Yang, Min Zhang, Hongyu Jin, Xuelei Ma & Hubing Shi. (2019) Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. Frontiers in Immunology 10.
Crossref
Masoud Najafi, Nasser Hashemi Goradel, Bagher Farhood, Eniseh Salehi, Somaye Solhjoo, Heidar Toolee, Ebrahim Kharazinejad & Keywan Mortezaee. (2018) Tumor microenvironment: Interactions and therapy. Journal of Cellular Physiology 234:5, pages 5700-5721.
Crossref
Adam Ajina & John Maher. 2019. Cancer Immunotherapy. Cancer Immunotherapy 217 292 .
Jessica Swanner, W. Hans Meisen, Ryan M. McCormack, Cole T. Lewis, Bangxing Hong & Balveen Kaur. 2019. Current Applications for Overcoming Resistance to Targeted Therapies. Current Applications for Overcoming Resistance to Targeted Therapies 63 96 .
Hanne Locy, Sven de Mey, Wout de Mey, Mark De Ridder, Kris Thielemans & Sarah K. Maenhout. (2018) Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend. Frontiers in Immunology 9.
Crossref
João Manuel Santos, Víctor Cervera-Carrascon, Riikka Havunen, Sadia Zafar, Mikko Siurala, Suvi Sorsa, Marjukka Anttila, Anna Kanerva & Akseli Hemminki. (2018) Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy. Molecular Therapy 26:9, pages 2243-2254.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.